Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Intellia Therapeutics, Inc.

Contributing Author

Recent Articles by Intellia Therapeutics, Inc.

Aug-07
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA +6.23% GlobeNewswire
Aug-06
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates NTLA GlobeNewswire
Jul-30
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates NTLA GlobeNewswire
Jul-06
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Jun-13
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema NTLA GlobeNewswire
Jun-05
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA -8.20% GlobeNewswire
Jun-01
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 NTLA GlobeNewswire
May-11
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates NTLA GlobeNewswire
May-05
Intellia Therapeutics to Participate in Upcoming Investor Conferences NTLA GlobeNewswire
May-01
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Apr-29
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock NTLA -5.72% GlobeNewswire
Apr-27
Intellia Announces Proposed Public Offering of Common Stock NTLA GlobeNewswire
Apr-27
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing NTLA GlobeNewswire
Apr-27
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema NTLA GlobeNewswire
Apr-24
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 NTLA -14.11% GlobeNewswire
Apr-03
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Mar-06
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Mar-03
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 NTLA -11.88% GlobeNewswire
Mar-02
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM NTLA +12.05% GlobeNewswire
Feb-26
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates NTLA +6.41% GlobeNewswire
Feb-24
Intellia Therapeutics to Participate in Upcoming Investor Conferences NTLA GlobeNewswire
Feb-19
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates NTLA GlobeNewswire
Feb-06
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA +10.73% GlobeNewswire
Jan-27
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN NTLA +6.31% GlobeNewswire
Jan-07
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference NTLA GlobeNewswire
Jan-02
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Dec-05
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Nov-10
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy NTLA GlobeNewswire
Nov-08
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema NTLA GlobeNewswire
Nov-06
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates NTLA -9.21% NTLA -22.73% GlobeNewswire
Oct-27
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) NTLA -42.23% GlobeNewswire
Oct-03
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Sep-25
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy NTLA -6.48% GlobeNewswire
Sep-22
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy NTLA +10.71% GlobeNewswire
Sep-18
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema NTLA +29.81% GlobeNewswire
Aug-07
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress NTLA GlobeNewswire
Aug-01
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Jul-31
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates NTLA -5.60% GlobeNewswire
Jul-07
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA NTLA +8.49% GlobeNewswire
Jun-15
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress NTLA GlobeNewswire
Jun-05
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA NTLA +6.73% GlobeNewswire
May-18
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting NTLA GlobeNewswire
May-08
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress NTLA +13.58% GlobeNewswire
May-06
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA -14.10% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)